Evolving Guidelines

Evolving Guidelines: The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors


This supplement reviews outcomes from several key trials, examines the use of PARP inhibitors and other emerging treatments, and discusses several changes recently made to treatment recommendations from NCCN and ASCO and how those changes can be incorporated into clinical practice.

Results 1 - 1 of 1